Q-omics provides the consensus-scored IMPDH1P5 profile across patient tissues and cancer cell-line models. IMPDH1P5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, IMPDH1P5 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, IMPDH1P5 RNA expression shows 17,303 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, THCA, and THYM as cancer lineages where IMPDH1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMPDH1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMPDH1P5 survival associations across molecular data types. IMPDH1P5 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMPDH1P5 RNA expression–survival associations across cancer types. High IMPDH1P5 expression shows unfavorable associations in LIHC, READ and MESO, but favorable associations in BRCA, HNSC and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for IMPDH1P5 RNA expression.
This table summarizes IMPDH1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IMPDH1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMPDH1P5 shows lower tumor expression in THCA and higher tumor expression in LUAD, KIRC, LUSC, HNSC and UCEC. The THCA box plot shows higher IMPDH1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.887, t-test p < 0.001).
This table shows molecular features associated with IMPDH1P5 in patient tissues and cancer cell lines. In patient samples, IMPDH1P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
